INCY - Incyte Corp Stock Price, Fair Value and News

68.62USD+0.05 (+0.07%)Market Closed

Market Summary

USD68.62+0.05

Market Closed

0.07%

INCY Alerts

1 major insider sales recently.

INCY Stock Price

View Fullscreen

INCY RSI Chart

INCY Valuation

Market Cap

15.4B

Price/Earnings (Trailing)

20.67

Price/Sales (Trailing)

4.09

EV/EBITDA

10.9

Price/Free Cashflow

18.77

INCY Price/Sales (Trailing)

INCY Profitability

Operating Margin

93.12%

EBT Margin

27.03%

Return on Equity

13.82%

Return on Assets

10.45%

Free Cashflow Yield

5.33%

INCY Fundamentals

INCY Revenue

Revenue (TTM)

3.8B

Rev. Growth (Yr)

8.93%

Rev. Growth (Qtr)

-13.07%

INCY Earnings

Earnings (TTM)

745.4M

Earnings Growth (Yr)

681.22%

Earnings Growth (Qtr)

-15.68%

Breaking Down INCY Revenue

Last 7 days

4.9%

Last 30 days

8.7%

Last 90 days

32.7%

Trailing 12 Months

9.2%

How does INCY drawdown profile look like?

INCY Financial Health

Current Ratio

3.47

Debt/Equity

Debt/Cashflow

45.4

INCY Investor Care

Shares Dilution (1Y)

0.65%

Diluted EPS (TTM)

3.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.8B	0	0	0
2023	3.5B	3.5B	3.6B	3.7B
2022	3.1B	3.3B	3.3B	3.4B
2021	2.7B	2.7B	2.9B	3.0B
2020	2.2B	2.4B	2.5B	2.7B
2019	2.0B	2.0B	2.1B	2.2B
2018	1.5B	1.7B	1.8B	1.9B
2017	1.2B	1.3B	1.4B	1.5B
2016	857.9M	941.2M	1.0B	1.1B
2015	581.0M	644.4M	633.8M	753.8M
2014	373.7M	371.6M	484.6M	511.5M
2013	332.0M	347.1M	371.7M	354.9M
2012	98.7M	168.4M	212.1M	297.1M
2011	184.6M	151.5M	151.4M	94.5M
2010	49.4M	89.6M	129.7M	169.9M
2009	0	0	0	9.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

CEO	Mr. Herve Hoppenot
WEBSITE	incyte.com
INDUSTRY	Biotechnology
EMPLOYEES	2324

Incyte Corp Frequently Asked Questions

What is the ticker symbol for Incyte Corp? What does INCY stand for in stocks?

INCY is the stock ticker symbol of Incyte Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Incyte Corp (INCY)?

As of Thu Jul 25 2024, market cap of Incyte Corp is 15.4 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INCY stock?

You can check INCY's fair value in chart for subscribers.

Is Incyte Corp a good stock to buy?

The fair value guage provides a quick view whether INCY is over valued or under valued. Whether Incyte Corp is cheap or expensive depends on the assumptions which impact Incyte Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INCY.

What is Incyte Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, INCY's PE ratio (Price to Earnings) is 20.65 and Price to Sales (PS) ratio is 4.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INCY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Incyte Corp's stock?

In the past 10 years, Incyte Corp has provided 0.038 (multiply by 100 for percentage) rate of return.